

*a3*

6. (Amended) The method of claims 1 or 2 wherein the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 2249417, SB 257731 or SB 257732.

7. (Amended) The method of claims 1 or 2 wherein the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249417.

Add the following new claims:

*a4*

--39. The method of claim 10 wherein the thrombosis is associated with stroke.

40. The method of claim 10 wherein the thrombosis is associated with sepsis.

41. The method of claim 1 wherein the anti-coagulation Factor IX/IXa antibody binds with an epitope of the Factor IX gla domain.

42. The method of claim 41 wherein the epitope is located within residues 3-11 of Factor IX.

43. The method of claim 42 wherein the antibody has a binding affinity of at least 4 nM.--

Remarks

Claims 1, 2, 6, 7, 10 and 39-43 are pending in this application after entry of this Amendment.

Claim 1 has been amended to more particularly point out and distinctly define the invention. Claims 6 and 7 have been amended to change their dependency from a now-cancelled claim. New claims 39-43 have been added.